Page last updated: 2024-12-11

vitamin mk 8

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vitamin MK 8: isoprenoid acetone-soluble lipid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

menaquinone-8 : A menaquinone whose side-chain contains 8 isoprene units in an all-trans-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5376507
CHEBI ID44027
SCHEMBL ID14164340
SCHEMBL ID10055449
MeSH IDM0082192

Synonyms (30)

Synonym
unii-sr2a44cb4u
sr2a44cb4u ,
1,4-naphthoquinone, 2-methyl-3-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-
1,4-naphthalenedione, 2-methyl-3-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-, (all-e)-
1,4-naphthalenedione, 2-methyl-3-((2e,6e,10e,14e,18e,22e,26e)- 3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-
menaquinone 8
mk-8
menaquinone-8
2-methyl-3-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaenyl]naphthalene-1,4-dione
2-methyl-3-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaen-1-yl]-1,4-naphthalenedione
vitamin mk 8
523-38-6
CHEBI:44027
2-methyl-3-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaen-1-yl]naphthalene-1,4-dione
mk 8
menaquinone mk8
(all-e)-2-methyl-3-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-1,4-naphthalenedione
vitamin k2(40)
SCHEMBL14164340
SCHEMBL10055449
2-methyl-3-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl]naphthoquinone #
LXKDFTDVRVLXFY-WQWYCSGDSA-N
2-methyl-3-[(2e,6e,10e,14e,18z,22e,26e)-3,7,11,15,19,23,27,31-octamethyldotriaconta-2,6,10,14,18,22,26,30-octaen-1-yl]naphthalene-1,4-dione
trans-menaquinone-8
Q27120539
2-methyl-3-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaen-1-yl)-1,4-naphthoquinone
A936882
vitamin mk-8
1,4-naphthalenedione, 2-methyl-3-[(2e,6e,10e,14e,18e,22e,26e)-3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaen-1-yl]-
vitaminmk8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
menaquinoneAny member of the class of menaquinones that is 2-methyl-1,4-naphthoquinone with an unsaturated isoprenoid chain at the 3-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
N-Oxide Electron Transfer2110
Dimethyl Sulfoxide Electron Transfer2210
menaquinone-8 biosynthesis22

Research

Studies (262)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (0.38)18.7374
1990's3 (1.15)18.2507
2000's13 (4.96)29.6817
2010's214 (81.68)24.3611
2020's31 (11.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.65 (24.57)
Research Supply Index5.57 (2.92)
Research Growth Index6.22 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other262 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]